Loading...
•
Dec 31, 2023
4DMT Q4 2023 Earnings Report
Reported full year 2023 financial results and provided operational highlights.
Key Takeaways
4D Molecular Therapeutics reported a transformative year in 2023, marked by significant progress in its product pipeline and platform across multiple therapeutic areas. The company highlighted positive interim data from the Phase 2 PRISM study of 4D-150 in wet AMD, advancements in clinical trials for 4D-710 in cystic fibrosis and 4D-310 in Fabry disease, and strategic agreements with Astellas Pharma and Arbor Biotechnologies. 4DMT's cash position was strengthened by a completed public follow-on offering, extending its operational runway into the first half of 2027.
Presented positive interim data from the Phase 2 PRISM study of 4D-150 in wet AMD, enabling Phase 3 pivotal development.
Demonstrated positive interim clinical data for 4D-710 in cystic fibrosis and 4D-310 in Fabry disease.
Secured strategic agreements with Astellas Pharma in rare monogenic retinal diseases and Arbor Biotechnologies in CNS gene editing.
Completed an upsized public follow-on offering, supplementing cash position and extending operational runway into the first half of 2027.
Revenue by Segment
Forward Guidance
4DMT anticipates several milestones in the near future across its key programs.
Positive Outlook
- Initial interim 24-week landmark analysis for Phase 2 PRISM Population Extension cohort of 4D-150 for Wet AMD expected in Q3 2024.
- Additional FDA and EMA regulatory interactions for 4D-150 planned in Q2 2024, with an update expected in Q3 2024.
- Phase 3 clinical trial initiation for 4D-150 for Wet AMD expected in Q1 2025.
- Initial interim 24-week landmark data for Phase 2 SPECTRA clinical trial Dose Confirmation cohort of 4D-150 for DME expected in H2 2024.
- FDA submission of preclinical NHP safety data for 4D-310 for Fabry Disease Cardiomyopathy in combination with rituximab/sirolimus immunosuppression regimen expected in Q2 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...